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Abstract Vanadium compounds show interesting bio-
logical and pharmacological properties. Some of them
display insulin-mimetic eﬀects and others produce anti-
tumor actions. The bioactivity of vanadium is present in
inorganic species like the vanadyl(IV) cation or vana-
date(V) anion. Nevertheless, the development of new
vanadium derivatives with organic ligands which im-
prove the beneﬁcial actions and decrease the toxic eﬀects
is of great interest. On the other hand, the mechanisms
involved in vanadium bioactivity are still poorly un-
derstood. A new vanadium complex of the vanadyl(IV)
cation with the disaccharide trehalose (TreVO), Na6
[VO(Tre)2].4H2O, here reported, shows interesting in-
sulin-mimetic properties in two osteoblast cell lines, a
normal one (MC3T3E1) and a tumoral one (UMR106).
The complex aﬀected the proliferation of both cell lines
in a diﬀerent manner. On tumoral cells, TreVO caused a
weak stimulation of growth at 5 lM but it inhibited cell
proliferation in a dose-response manner between 50 and
100 lM. TreVO signiﬁcantly inhibited UMR106 diﬀer-
entiation (15–25% of basal) in the range 5–100 lM. On
normal osteoblasts, TreVO behaved as a mitogen at
5–25 lM. Diﬀerent inhibitors of the MAPK pathway
blocked this eﬀect. At higher concentrations
(75–100 lM), the complex was a weak inhibitor of the
MC3T3E1 proliferation. Besides, TreVO enhanced
glucose consumption by a mechanism independent of
the PI3-kinase activation. In both cell lines, TreVO
stimulated the ERK phosphorylation in a dose- and
time-dependent manner. Diﬀerent inhibitors (PD98059,
wortmannin, vitamins C and E) partially decreased this
eﬀect, which was totally inhibited by their combination.
These results suggest that TreVO could be a potential
candidate for therapeutic treatments.
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Introduction
Vanadium is an ultra trace element present in higher
plants and animals [1, 2]. It has been demonstrated that
vanadium compounds present interesting biological and
pharmacological properties. In particular, they show
insulin-mimetic activity both in vivo and in vitro studies
[3, 4, 5, 6]. Vanadium promotes glucose transport and
metabolism, lipid synthesis, DNA and protein synthesis
and has also mitogenic eﬀects on diﬀerent cell types [7, 8,
9, 10, 11, 12, 13]. In vitro studies have shown that both
vanadate and vanadyl decrease lipolysis and stimulate
glucose oxidation, glucose transport, glycogen synthase
and tyrosine phosphorylation in rat adipocytes [14, 15,
16]. In addition, vanadate stimulates glucose uptake,
glycogen synthase, glycolysis and glucose oxidation in
skeletal muscle [17].
At pharmacological concentrations, vanadium deriv-
atives are interesting as potential therapeutic agents.
Many vanadium compounds behave as insulin mimics
and others display antitumor activity [18, 19]. Once
absorbed, vanadium compounds distribute among
diﬀerent tissues and, ﬁnally, vanadium is mainly stored in
bone [1]. It has been previously shown that vanadium
deprivation induced skeletal deformation in the forelegs
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of goats [20]. We have earlier reported the eﬀect of
diﬀerent vanadium derivatives on bone-related cells like
ﬁbroblasts andosteoblasts in culture [13, 21, 22, 23, 24, 25,
26, 27], with vanadium(V) compounds being in general
more toxic than vanadium(IV) complexes. Besides, at low
concentrations, most vanadium derivatives are weak
mitogens in comparison with insulin and exert cytotoxic
eﬀects at high concentrations. They also inhibit osteob-
lastic diﬀerentiation, induce morphological alterations
and stimulate glucose consumption.
As is well known, insulin signal transduction is
mediated through a complex cascade network of
reversible protein phosphorylations and dephosphory-
lations. The earliest event in insulin actions is the
autophosphorylation and stimulation of the tyrosine
kinase activity of the b-subunit insulin receptor, induced
by insulin binding to the a-subunit [28]. Subsequently,
insulin receptor tyrosine kinase phosphorylates endog-
enous substrates such as IRS-1 (insulin receptor sub-
strate-1), which has been the most widely characterized.
After that, a cascade of phosphorylation takes place
downstream; protein kinases activated by mitogens
(MAPK) and ribosomal protein kinases (p90rsk) become
activated, which, in turn, induce diﬀerent events. Most
evidence suggests that phosphatidyl inositol-3 kinase
(PI3-K) is the major link between IRS-1 and the meta-
bolic eﬀects of insulin, while GRB2 (the molecule that
connects IRS-1 to the Ras pathway) may be the major
link to the growth promotion eﬀect of insulin [28].
Numerous studies have been carried out in order to
elucidate the putative mechanisms of action of
vanadium derivatives. The insulin-mimetic eﬀects of
vanadium would be the result of its behavior as a
phosphate analogue and as such it can stimulate the
protein tyrosine phosphorylation through the inhibition
of protein tyrosine phosphatases (PTPases) [29, 30] or
by direct stimulation of the kinases [31]. In vitro and in
vivo studies demonstrated that vanadium aﬀects
diﬀerent aspects of the insulin signalling pathway.
MAPK cascade is one of the major signalling pathways
apparently involved in vanadium biological eﬀects. The
major subfamilies of structurally related MAPKs that
have been identiﬁed in mammalian cells are the extra-
cellular signal-regulated kinases (ERKs), the c-jum
N-terminal kinases (JNKs) and the p38 MAPkinases
(p38s) [32, 33, 34]. ERKs are activated by various
growth factors, which act through receptor tyrosine
kinases (RTKs) like the platelet-derived growth factor
(PDGF) [35, 36] and the insulin-like growth factor-1
(IGF-1) [37]. Moreover, the ERK pathway is usually
associated with cell proliferation and protection from
apoptosis [38].
Srivastava and co-workers [39] reported that the
stimulation of the ras-ERK cascade by vanadyl sulfate
is dependent on PI3-K activation and it is suggested
that the stimulation of the PI3-K/ras/ERK pathway
plays a key role in mediating the insulin-mimetic eﬀects
of inorganic vanadium salts. It has been shown that
several vanadium salts activate MAPK and two ribos-
omal protein kinases, including p90rsk, in an IR kinase-
independent manner [40, 41, 42, 43, 44].
On the other hand, vanadium compounds also show
some toxic eﬀects, which depend on several factors such
as the oxidation state, the coordination sphere and the cell
type or tissue investigated [6, 45, 46]. Studies with vana-
dium(IV) complexes of ascorbic acid and monosaccha-
rides have demonstrated that these compounds cause
substantial single-strand breaks in DNA and produce
lipid peroxidation [47]. However, some of the known
monosaccharide complexes of vanadium(IV) also present
an interesting protective activity against the degradation
of RNA because they inhibit RNase activity [48].
Various organically chelated vanadium compounds
are more potent to facilitate insulin-like eﬀects in vitro
and in vivo than the simple vanadium salts [49, 50, 51].
Since vanadium absorption is poor in the gastrointestinal
tract, the use of organic ligands should increase the
lipophilicity of vanadium increasing the gastrointestinal
absorption, and thereby decreasing the dose of vanadium
required to produce its eﬀects [52]. The synthesis of va-
nadium complexes with sugars [53, 54, 55] is of consid-
erable interest in vanadium biochemistry because they
are easily and quickly assimilated by plants and animals
and especially in relation to the vanadium metabolism
and its biological detoxiﬁcation [56, 57, 58].
The present study deals with the synthesis and
the physicochemical characterization of a new
vanadium(IV) complex with the disaccharide trehalose
(a-D-glucopyranosyl-a-D-glucopyranoside) (Fig. 1),
and also with the study of its biological eﬀects and
putative mechanism of action on osteoblast-like cells in
culture.
Fig. 1 Trehalose (a-D-glucopyranosyl-a-D-glucopyranoside) dihy-
drate. After [74]
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Materials and methods
Materials
VOCl2 (50% aqueous solution) was purchased from Carlo Erba;
trehalose dihydrate, crystal violet, p-nitrophenyl phosphate
(p-NPP), glycine, MgCl2 and all the other chemicals used were of
analytical grade from Sigma.
Fresh stock solutions of the complex (TreVO) and the free
ligand (trehalose) were prepared in distilled water at a 100 mM
concentration and diluted according to the concentrations
indicated in the legends to the ﬁgures.
Tissue culture materials were purchased from Corning
(Princeton, NJ, USA), Dulbecco’s Modiﬁed Eagles Medium
(DMEM), DMEM low glucose and trypsin-EDTA from Gibco
(Gaithersburg, Md., USA) and fetal bovine serum (FBS) from
GibcoBRL (Life Technologies, Germany). An ECL kit was pro-
vided by Amersham Life Sciences. The speciﬁc antibody rabbit
polyclonal IgG anti-ERK (K-23), mouse monoclonal anti-p-ERK
(E-4), anti-rabbit IgG-HRP and anti-mouse IgG-HRP were pur-
chased from Santa Cruz Biotechnology. PD98059 was obtained
from Calbiochem (USA and Canada), wortmannin and L-ascorbic
acid (vitamin C) from Sigma. (+)-a-Tocopherol acid succinate
(vitamin E) was a gift from Scherer (Buenos Aires, Argentina).
Wiener Laboratories (Argentina) provided the glucose oxidase kit.
Synthesis of TreVO: Na6[VO(Tre)2].4H2O
VOCl2 (50% aqueous solution, 2 mmol) was added dropwise to a
stirred aqueous solution (10 mL) of trehalose (4 mmol). The so-
lution pH was adjusted to 13 by addition of solid NaOH. Upon the
addition of absolute ethanol, a microcrystalline powder was
formed. The solid was ﬁltered and washed with absolute ethanol.
The hygroscopic sodium salt of the complex was stored in an oven
at 60 C until its physicochemical characterization; yield: 90%.
Physicochemical characterization
Diﬀuse reﬂectance spectra were recorded on a Shimadzu UV-300
spectrophotometer. Infrared spectra were recorded on a Perkin-
Elmer 580B spectrophotometer using the KBr pellet technique.
Room temperature magnetic susceptibility was determined with a
Cahn-2000 balance, calibrated with Hg[Co(SCN)4] and at a
magnetic ﬁeld strength of 6 kG. Elemental analysis for carbon
and hydrogen were performed using a Carlo Erba EA 1108 an-
alyzer. Flame photometry and the tungstophosphovanadic meth-
od [59, 60] were employed to determine sodium and vanadium
contents, respectively. Thermogravimetric (TGA) and diﬀerential
thermal analysis (DTA) were performed on a Shimadzu system
(models TG-50 and DTA-50, respectively), working in an oxygen
ﬂow of 60 mL/min and at a heating rate of 10 C/min. Sample
quantities ranged between 10 and 20 mg. Al2O3 was used as a
DTA standard.
Cell culture
MC3T3E1 osteoblastic mouse calvaria-derived cells and UMR106
rat osteosarcoma-derived cells were grown in DMEM supple-
mented with 100 U/mL penicillin, 100 lg/mL streptomycin and
10% (v/v) fetal bovine serum (FBS) at 37 C, 5% CO2. When
70–80% conﬂuence was reached, the cells were sub-cultured using
0.1% trypsin+1 mM EDTA in Ca2+/Mg2+-free phosphate buf-
fered saline (PBS) (11 mM KH2PO4, 26 mM Na2HPO4, 115 mM
NaCl, pH 7.4) [13, 22]. For experiments the cells were grown in
multi-well plates. When the cells reached 70% conﬂuence, the
monolayers were washed twice with DMEM and were incubated
under diﬀerent conditions according to the experiments.
Cell proliferation assay
A mitogenic bioassay was carried out as described by Okajima et al.
[61], with some modiﬁcations. Brieﬂy, the cells were grown in
48-well plates. When the cells reached 60% conﬂuence, the
monolayers were washed twice with serum-free DMEM and incu-
bated either with diﬀerent concentrations of TreVO (2.5–100 lM)
alone, or TreVO plus PD98059 (10 lM), wortmannin (1 lM) or a
mixture of vitamins E and C (50 lM each), according to the ﬁgure
legends. Then, the monolayers were washed with PBS buﬀer and
ﬁxed with 5% glutaraldehyde/PBS at room temperature for 10 min.
After that, they were stained with 0.5% crystal violet/25% meth-
anol for 10 min. Then the dye solution was discarded and the plate
was washed with water and dried. The dye taken up by the cells was
extracted using 0.5 mL/well 0.1 M glycine/HCl buﬀer, pH 3.0, in
30% methanol and transferred to test tubes. Absorbance was read
at 540 nm after a convenient sample dilution. We have previously
shown that under these conditions the colorimetric bioassay
strongly correlated with the cell proliferation measured by cell
counting in a Neubauer chamber [13, 22].
Cell diﬀerentiation assay
Alkaline phosphatase (ALP) speciﬁc activity has been used as a
marker of osteoblast phenotype [13, 22, 62]. Cells were grown in
24-well plates until 70–80% conﬂuence, and the monolayers were
washed twice with serum-free DMEM. Then the cells were incu-
bated overnight with serum-free DMEM and diﬀerent doses of
TreVO (2.5–100 lM) alone, or TreVO plus PD98059 (10 lM),
wortmannin (1 lM) or a mixture of vitamins E and C (50 lM
each), according to the ﬁgure legends. The cell layer was then
washed with PBS and solubilized in 0.5 mL 0.1% Triton X-100.
Aliquots of the total cell extract (10–20%) were used for protein
determination by the Bradford technique [63]. Measurement of
ALP activity was carried out by spectrophotometric determination
of initial rates of hydrolysis of p-NPP to p-nitrophenol (p-NP) at
37 C for 10 min. The reaction mixture consisted of 10 lL of cell
extract in 800 lL of glycine buﬀer (55 mM glycine, 0.55 mM
MgCl2, pH 10.5). The reaction was initiated by the addition of
100 lL of substrate solution to 5 mM p-NPP in glycine buﬀer. The
production of p-NP was determined by the absorbance at 405 nm.
Under these experimental conditions the product formation was
linear for 15 min.
Glucose consumption assay
Cells were subcultured in 48-well plates. When the cells reached
90% conﬂuence, the monolayers were washed twice with serum-
free DMEM low glucose. Then they were incubated in serum-free
DMEM low glucose either with diﬀerent concentrations of TreVO
(2.5–100 lM) alone, or TreVO plus PD98059 (10 lM), wortman-
nin (1 lM) or a mixture of vitamins E and C (50 lM each), ac-
cording to the ﬁgure legends. After 10 h at 37 C, the conditioned
medium was removed and centrifuged at 5000·g for 3 min. The cell
layer was then washed with PBS and solubilized in 0.5 mL 0.1%
Triton X-100. Aliquots of the total cell extract were kept for pro-
tein determination using the Bradford technique [63]. The glucose
concentration remaining in the conditioned medium was measured
by the glucose oxidase enzymatic method, as described previously
[61].
Western blotting of cell lysates
MC3T3E1 and UMR106 osteoblastic-like cells were subcultured
into 12-well plates in DMEM supplemented with 100 U/mL peni-
cillin, 100 lg/mL streptomycin and 10% (v/v) FBS at 37 C, 5%
CO2. When 100% conﬂuence was reached, the medium was re-
moved and the cells were washed twice with serum-free DMEM.
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The cells were incubated in serum-free DMEM either with insulin,
diﬀerent concentrations of TreVO alone or TreVO plus PD98059,
wortmannin or a mixture of vitamins E and C, for diﬀerent periods,
according to the ﬁgure legends. The cells were washed twice with
cold PBS and lysed in Laemmli buﬀer [64]. Protein content was
determined in each lysated cellular fraction. Aliquots with equal
amounts of protein were separated on 12.5% SDS-PAGE under
reducing conditions. Then they were transferred to nitro-cellulose
membranes, and examined by immunoblotting with speciﬁc anti-
bodies against the phosphorylated (1:3000) and non-phosphory-
lated (1:1000) ERK-1/2 and revealed by an ECL commercial kit.
Stability studies
To test the stability of TreVO under the diﬀerent experimental
conditions used in this work we analyzed the pH and UV-visible
spectra of diﬀerent solutions of the complex. TreVO (50 mM) so-
lutions in distilled water, DMEM medium and DMEM plus 0.5%
DMSO, 50 lM PD98059 and a mixture of vitamins C and E
(50 lM each) were prepared. The electronic spectra were recorded
at times ranging from 0 to 48 h. The rate of decomposition of
TreVO was spectrophotometrically measured at 720 nm (this
wavelength corresponds to the b2 ﬁ e electronic absorption band
[53, 54, 55]). The decomposition rate constants were estimated.
We also studied the pH changes under diﬀerent experimental
conditions.
Statistical methods
At least three independent experiments were performed for each
experimental condition. Results are expressed as the mean±SEM.
Statistical diﬀerences were analyzed using Student’s t-test.
Results
Elemental analysis
Anal. calcd. for C24H44Na6O27V (953): C, 30.2; H, 4.6;
Na, 14.5; V, 5.3%. Found: C, 29.9; H, 4.8; Na, 14.6; V,
5.2%. These results account for the molecular formula
Na6[VO(Tre)2].4H2O, later conﬁrmed through the ther-
mal decomposition results (see below).
Magnetic susceptibility
The sodium salt shows a magnetic moment leﬀ=1.9 BM
at room temperature. This value indicates that the va-
nadium center is in a d1 electronic conﬁguration [60].
The experimental leﬀ is close to the spin-only value,
1.73 BM, at room temperature.
Thermal behavior
The TGA plot under oxygen ﬂow shows two degrada-
tion steps at 50 C and 121 C. These steps correspond
ﬁrst to the loss of a water molecule (1.9% obs., 1.9%
calcd.) and then to the three remaining ones, respectively
(5.6% obs., 5.7% calcd.). The degradation of the an-
hydrous complex occurs in three steps in the ranges
176–471, 471–566 and 566–1000 C. DTA signals were:
233 w, exo; 293 vs, exo. The total weight loss corre-
sponds to the formation of NaVO3, as detected by IR
spectroscopy. The overall degradation process corre-
sponds to the following equation:
2Na6 VO Treð Þ2
 
:4H2O!O2 2NaVO3 þ 5Na2O ð1Þ
The observed ﬁnal weight (29.1%) agrees with the
calculated value (29.1%).
Diﬀuse reﬂectance
The spectrum of the complex shows the three bands
typical of sugar complexes with the vanadyl(IV) cation
[53, 54, 55]. These bands are centered at 420, 500 and
740 nm.
Infrared studies
The vibrational spectrum of the vanadyl(IV) complex,
TreVO, and that of the free ligand, Tre, can be seen in
Fig. 2. The bands at 805 cm)1 and 910 cm)1 indicate
that the glucose moieties of trehalose are present as the
a-anomer in the pyranose form. Moreover, the band at
845 cm)1 is indicative of the a-conﬁguration of the
Fig. 2 IR spectra of trehalose (Tre) and Na6[VO(Tre)2].4H2O
(TreVO). Transmittance in arbitrary units. Single asterisks: bands
that change upon complexation. Double asterisks: new band, V=O
stretching. Solid spots: unchanged bands
462
glycosidic bond of the disaccharide [65, 66, 67, 68, 69,
70, 71, 72]. These bands have not changed upon com-
plexation. In the TreVO IR spectrum, the band at
1398 cm)1 [dC(2)H] disappears upon complexation. The
bands at 1355 cm)1 and 1013 cm)1 (dCOH) are sensitive
to deuteration [71], and to the coordination to the metal
center. By complexation the dCOH [C(6)H2OH] band at
1309 cm)1 disappears owing to the deprotonation of the
OH groups. Finally, the new band observed at 941 cm)1
corresponds to the m(V=O) stretching mode. The posi-
tion of this band is similar that of other vanadyl(IV)
complexes with saccharides previously reported by our
group ([53, 54, 55] and references therein).
These observations suggest that the cation is coordi-
nated by the ligand through the deprotonated OH group
at C(2). It is well known that, in the case of neutral
sugars, complexation is favored by basic media and
occurs only with molecules possessing adjacent cis-
hydroxyl groups [53, 54, 55]. Considering that there is
not another OH group in a cis position near C(2), it is
diﬃcult to determine with certainty the other chelating
group belonging to the second glucose moiety of treha-
lose. The crystal structure of a,a-trehalose dihydrate has
been previously described in detail [73, 74, 75]. It has
been demonstrated that, apart from the glycosidic bond
between C(1) and C(1’), the two glucopyranosyl moieties
of threhalose are also indirectly linked through hydro-
gen bonds of the two water molecules of the dihydrate.
One bound water molecule (w1) is linked by hydrogen
bonding to both O(2) and to O(4’). The other bound
water molecule (w2) is linked to both O(2) and to O(6’)
(Fig. 1). It is reasonable to think that in TreVO the
vanadyl(IV) cation interacts with O(2) and it may form
the chelate through O(4’) or O(6’). These groups con-
stitute cis pairs of donors adequate for this interaction.
Eﬀect of TreVO on the osteoblast-like
cell proliferation
Figure 3 shows the eﬀect of diﬀerent TreVO concen-
trations on the proliferation of MC3T3E1 and UMR106
osteoblast-like cells, determined by crystal violet bioas-
say. After a 24-h culture, 5 lM TreVO signiﬁcantly in-
creased UMR106 cell proliferation (105% over basal,
P<0.05). A stronger mitogenic eﬀect was observed in
the non-transformed MC3T3E1 line, in which 5–25 lM
TreVO signiﬁcantly stimulated cell growth, ranging
from 111 to 114% over basal (P<0.01). On the other
hand, higher doses of the vanadium complex showed a
cytotoxic eﬀect on both osteoblastic lines, although this
eﬀect was stronger in the UMR106 than in the
MC3T3E1 cells. Thus, at 75–100 lM concentrations, a
slight but statistically signiﬁcant inhibition of MC3T3E1
growth (10%, P<0.02) was observed, while 50–100 lM
TreVO decreased UMR106 cell proliferation in the
range 20–45% of control (P<0.002). Moreover, the free
ligand (trehalose) did not exert any eﬀect on either cell
line in the whole range of tested concentrations. In
previous work we have reported that the vanadyl(IV)
cation stimulated UMR106 proliferation in the same
range [13, 23]. In MC3T3E1 cells, the vanadyl(IV) cation
was an inhibitory agent in the range 10–100 lM [25].
In an attempt to deﬁne the mechanism by which
TreVO stimulates MC3T3E1 cell proliferation, we next
examined the eﬀect of diﬀerent inhibitors of the ERK
pathway such as wortmannin, PD98059 and also the
eﬀect of a mixture of vitamins E and C (free radical
scavengers). As can bee seen in Fig. 3, at 25 lM con-
centration, TreVO signiﬁcantly increased cell prolifera-
tion (118% over basal, P<0.01). This stimulatory eﬀect
was totally abolished by either PD98059 or wortmannin,
but not by a mixture of vitamins C and E. These ob-
servations suggest the involvement of a PI3K-ERK
pathway in the mitogenic action of TreVO. In control
experiments, the eﬀect of ERK inhibitors or the mixture
of vitamins (without vanadium complex) was also eval-
uated for possible cytotoxicity. It should be noted that,
under these conditions, none of these agents aﬀected cell
growth (Fig. 4).
On the other hand, we also investigated the mecha-
nism by which higher doses of TreVO-induced osteob-
lastic cytotoxicity. However, wortmannin, PD98059 or a
mixture of vitamins E and C did not prevent this eﬀect
for the vanadium complex.
Eﬀect of TreVO on osteoblastic diﬀerentiation
The eﬀect of the trehalose vanadium(IV) complex on
osteoblast-like cell diﬀerentiation was assessed by ALP
speciﬁc activity, as described in Materials and methods.
As can be seen from Fig. 5, TreVO (5–100 lM) signiﬁ-
cantly inhibited UMR106 cell diﬀerentiation in the
Fig. 3 Eﬀect of TreVO on MC3T3E1 and UMR106 osteoblast-like
cell proliferation. Cells were incubated in serum-free DMEM alone
(basal) or with diﬀerent concentrations of TreVO at 37 C for 24 h.
Results are expressed as % basal and represent the mean±SEM
(n=12)
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range of 15–25% of basal (P<0.001). These results are
in agreement with our previous studies in which the
vanadyl cation was shown to be a weak inhibitor of the
osteoblastic diﬀerentiation [13, 23] in comparison with
vanadium(V) compounds. Since the MC3T3E1 cells do
not express measurable ALP levels after short culture
periods (3 days) [76], the eﬀect of TreVO was not as-
sessed in this cell line.
TreVO and insulin stimulate glucose consumption
in osteoblast-like cells by a mechanism independent
of PI3-K
We next determined whether or not TreVO was able to
stimulate glucose consumption in osteoblast-like cells in
culture. The vanadium complex increased glucose con-
sumption at a similar extent in both MC3T3E1 and
UMR106 osteoblastic lines. Figure 6 shows the results
of diﬀerent concentrations of TreVO and 10)7 M insulin
on the glucose consumption in UMR106 cells. TreVO
increased the consumption of glucose in a dose-depen-
dent manner, with a maximum eﬀect at a concentration
of 25 lM.
In an attempt to deﬁne the mechanism of action of
TreVO-stimulated glucose consumption, we studied the
eﬀect of wortmannin over this parameter. UMR106
osteoblast-like cells were pre-incubated with diﬀerent
concentrations of wortmannin (0.1, 1 and 10 lM) dur-
ing several periods of time (0.5, 1 and 3 h) followed by a
10-h culture of either 25 lM TreVO or 10)7 M insulin.
Stimulation of glucose consumption by insulin or
TreVO was not aﬀected by wortmannin under any of the
above conditions. These results are in contrast to pre-
vious observations in other cell types [77, 78], and sug-
gest that insulin and TreVO could stimulate glucose
consumption in UMR106 and MC3T3E1 osteoblast-like
cells without activating PI3-K.
TreVO-induced activation of ERK-1/2
in osteoblast-like cells
To investigate the signal transduction pathways involved
in the mechanism of action of the TreVO complex, we
Fig. 5 Eﬀect of TreVO on osteoblast-like cell diﬀerentiation.
UMR106 cells were incubated either in serum-free DMEM alone
(basal) or with diﬀerent concentrations of TreVO at 37 C for 24 h.
Basal activity was 1 lmol pNP/min·mg protein. Results are
expressed as % basal and represent the mean±SEM (n=9)
Fig. 4 Eﬀect of inhibitors on TreVO-induced MC3T3E1 cell
proliferation. Osteoblast-like cells were incubated at 37 C for
24 h in DMEM alone (basal), DMEM plus PD98059 (10 lM) or
wortmannin (1 lM), or a mixture of vitamins E and C (50 lM
each) (controls), and in DMEM plus TreVO or TreVO plus
inhibitors. Cell proliferation was determined by the crystal violet
bioassay. Results are expressed as % basal and represent the
mean±SEM (n=9)
Fig. 6 Eﬀect of TreVO on glucose consumption. UMR106 cells
were incubated either with DMEM alone (basal), 10)7 M insulin or
diﬀerent concentrations of TreVO at 37 C for 10 h. Basal glucose
consumption was 1.2±0.06 mg glucose/mg protein. Results are
expressed as % basal and represent the mean±SEM (n=9)
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examined its eﬀect on the activation of ERK. Proteins in
the cell extracts were separated by electrophoresis and
examined by immunoblotting with speciﬁc antibodies
against the phosphorylated and non-phosphorylated
forms of ERK-1/2. A representative immunoblot is
shown for ERK and p-ERK in Fig. 7. TreVO stimulated
the ERK phosphorylation in a dose-dependent manner
(Fig. 7A), from 50 to 1000 lM. This eﬀect was also
dependent on the time of incubation (Fig. 7B). As can
be seen, the maximum eﬀect of 500 lM was reached at a
1-h incubation and began to decline thereafter.
In an attempt to deﬁne the mechanism by which
TreVO induced ERK phosphorylation, we examined the
potential role of both oxidative and MAPK pathways.
Osteoblasts were pre-incubated either with a mixture of
vitamins E and C (free radical scavengers), wortmannin
(a PI3-K inhibitor), PD98059 (a MEK inhibitor) or a
combination of the previous conditions. Control exper-
iments were also carried out with a mixture of vitamins
E and C, wortmannin, PD98059, a vehicle (DMSO) and
their combination. Finally, 25 or 1000 lM TreVO were
added for an additional 1 h and the activation of ERK
was assessed as before.
Figure 8 shows the eﬀect of the inhibitors on the
ERK phosphorylation induced by low doses (25 lM) of
TreVO in the MC3T3E1 cell line. The stimulatory eﬀect
(175% over basal, P<0.001) of the vanadium complex
was totally blunted by either PD98059 or wortmannin.
However, the mixture of vitamins E and C did not aﬀect
the TreVO-induced ERK activation. These results sug-
gest that the eﬀect of low doses of the TreVO complex
could occur through the PI3K-MEK-ERK pathway and
seems to be independent of the formation of free radicals
in these cells.
On the other hand, the ERK phosphorylation in-
duced by high concentrations of TreVO (1000 lM) was
partially inhibited by wortmannin, PD98059 or a mix-
ture of vitamins (Fig. 9). An additive eﬀect could be
observed when the cells were incubated with the mixture
of inhibitors, thus totally abrogating the eﬀect of TreVO
on ERK activation. For comparison, the eﬀect of insulin
in the osteoblastic cells was also investigated. Insulin
(10)7 M) stimulated ERK phosphorylation fourfold, an
eﬀect that was inhibited by either wortmannin or
PD98059, but not by a mixture of vitamins E and C.
Altogether, these results suggest that the activation of
ERK at higher concentrations of TreVO could occur
through at least two mechanisms, one dependent on and
the other independent of the oxidative stress.
Stability of TreVO under diﬀerent experimental
conditions
Under our experimental conditions, the decomposition
reaction of TreVO is ﬁrst order in the concentration of
the complex. This dependence is demonstrated by the
linearity of the plots of lnA versus time, where A is the
absorbance at 720 nm, measured at time t. The decom-
position rate of the complex was determined in distilled
water at 25 C, since the stock solution was prepared in
this solvent at room temperature. Nevertheless, once
prepared, the stock solution was immediately added to
Fig. 7 Dose-response (A) and time course (B) of TreVO-induced
ERK phosphorylation. Conﬂuent UMR106 cells were treated with
diﬀerent concentrations of TreVO for 1 h (A) or with 500 lM
TreVO for diﬀerent periods of time (B). Cells were lysed and
proteins were separated by SDS-PAGE and transferred to
nitrocellulose membrane. For immunoblots, either anti-phospho-
ERK or anti-ERK antibodies were used for previous stripping.
Relative intensities of stimulation were corrected for total ERK, as
determined by densitometry and are expressed as % basal. Similar
results were obtained in three independent experiments performed
by triplicates
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the culture medium at 37 C. The rate constant for the
decomposition of a 50 mM TreVO solution in distilled
water at 25 C was k=1.1·10)4 min)1. On the other
hand, in DMEM medium at 37 C the k value was
2.3·10)4 min)1 and in DMEM plus diﬀerent inhibitors
it was 2.8·10)4 min)1. Altogether, these results show
that although TreVO is stable under our working con-
ditions, its semi-decomposition time is greater in the
presence of the oxygen scavengers (vitamins C and E).
On the other hand, the stock solution of 100 mM
TreVO in distilled water has a pH of 11.0. At the max-
imum concentration used in this work (1 mM of the
complex in DMEM for Western blot experiments),
TreVO caused a transitory change of pH from 7.4 to 8.5
for less than 3 min. Besides, the complex at 100 lM,
which is the highest concentration used in the prolifer-
ation, diﬀerentiation and glucose consumption assays,
did not cause any change in the pH value of the culture
medium.
Discussion
Many studies carried out in diﬀerent laboratories have
previously demonstrated the insulin-mimetic properties
of inorganic vanadium salts on diﬀerent cell types [5, 6,
7, 8, 9, 10, 11, 12]. Vanadium compounds exert
mitogenic actions, behaving as growth factor mimetic
compounds and as metabolic agents. In particular, we
have shown their eﬀects on cell proliferation and dif-
ferentiation as well as on the stimulation of glucose
consumption in osteoblast-like cells in culture [13, 21,
22, 23, 24, 25, 26, 27].
As part of a research project devoted to develop new
vanadium derivatives with simple sugars and related
compounds, we have synthesized and characterized
several complexes of the vanadyl(IV) cation with this
type of ligand [53, 54, 55]. In this paper, we have syn-
thesized and characterized a new complex of vana-
dyl(IV) with the disaccharide trehalose, which displays
interesting biological activities.
As we have stated above (see Results), the vanadyl
cation is linked to trehalose O(2). Comparing the
conformation adopted by this ligand in the reported
structure of its dihydrate complex, we assume the
participation of either the O(4’) or O(6’) in chelate
formation [73, 74, 75].
To determinate the insulin-mimetic activity of TreVO
and to investigate its mechanism of action, we have used
two osteoblast-like cell lines in culture. One of them is a
line derived from mouse calvaria (MC3T3E1) and the
other from a rat osteosarcoma (UMR106). We have
previously determined the eﬀects upon cellular growth
of diﬀerent vanadium(IV) derivatives [13, 23, 24]. At low
doses (5–25 lM), the free vanadyl(IV) cation and va-
nadium compounds stimulate the UMR106 cell prolif-
eration but not the proliferation of the non-transformed
MC3T3E1 osteoblasts. In these cells, at low doses,
Fig. 9 Eﬀect of inhibitors on ERK activation induced by high
doses of TreVO (1 mM). MC3T3E1 osteoblast-like cells were pre-
incubated either with PD98059 (50 lM) for 1 h, wortmannin
(10 lM) for 1 h, a mixture of vitamins E and C (50 lM each) for
6 h, a combination of the previous conditions in serum-free
DMEM (basal) or plus 1000 lM TreVO for 1 additional hour.
Immunoblots were performed as described in Materials and
methods. Relative intensity of stimulation corrected for total
ERK was determined by densitometry. Results are expressed as %
basal and are representative of three independent experiments
Fig. 8 Eﬀect of inhibitors on ERK activation induced by low doses
of TreVO. MC3T3E1 osteoblast-like cells were pre-incubated either
with PD98059 (50 lM) for 1 h, wortmannin (10 lM) for 1 h or a
mixture of vitamins E and C (50 lM each) for 6 h, in serum-free
DMEM (basal) or plus 25 lM TreVO for 1 additional hour.
Immunoblots were performed as described in Materials and
methods. The relative intensity of stimulation corrected for total
ERK was determined by densitometry. Results are expressed as %
basal and are representative of three independent experiments
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TreVO was an eﬀective stimulatory agent on the
MC3T3E1 proliferation with a weaker eﬀect on the tu-
morigenic line UMR106. In addition, at higher con-
centrations (75–100 lM), TreVO was a more potent
inhibitor of UMR106 growth than of MC3T3E1 cell
proliferation. A selective action of TreVO on cell pro-
liferation, which depends on the concentration and the
cellular type, can be seen. These results show that the
coordination of vanadyl(IV) with trehalose produced a
new complex of vanadium with interesting mitogenic
activity.
The signalling mechanism by which vanadium com-
pounds stimulate cell proliferation is at present poorly
understood. It has been suggested that one of the pos-
sible mechanisms involved in vanadium bioactivity is the
regulation of the phosphotyrosine protein level [79]. The
insulin-mimetic eﬀects of vanadium may be attributed to
its analogy with phosphate and to the stimulation of
protein tyrosine phosphorylation through the inhibition
of protein tyrosine phosphatases (PTPases) [29, 30] or to
the direct stimulation of the kinases [31]. Alternatively,
diﬀerent authors have suggested that the molecular
mechanism by which vanadium exerts its biological ef-
fects may be due to the formation of reactive oxygen
species [80, 81, 82]. Other investigators and our group
have brought data towards this direction, demonstrating
the induction of thiobarbituric acid reactive substances
(TBARS) and reactive oxygen species (ROS) formation
upon incubation with diﬀerent vanadium compounds
[46, 83]. It has been previously shown [39] that the ac-
tivation of ERK by vanadyl sulfate is dependent on PI3-
K activation. On the other hand, various growth factors
like platelet-derived growth factor (PDGF) and insulin-
like growth factor-I (IGF-I), which act through the re-
ceptor tyrosine kinases (RTKs), are able to activate
ERK’s [35, 36, 37, 38]. The ERK pathway is usually
associated with cell proliferation and protection from
apoptosis [28, 84].
In our model of osteoblastic cells in culture we have
demonstrated the ability of low doses of TreVO to
stimulate ERK phosphorylation in MC3T3E1 cell line.
This eﬀect was totally abrogated by an inhibitor of
MEK (PD98059) and wortmannin, but not by a mix-
ture of free radical scavengers (vitamins E and C)
(Fig. 8). These results suggest that low doses of the
complex, which are mitogenic for MC3T3E1 cells,
could act though the PI3K-MEK-ERK pathway and
by a mechanism independent of free radicals. On the
other hand, at higher doses, TreVO inhibited cell pro-
liferation in both cell lines. This eﬀect was not blocked
by either wortmannin or PD98059, nor by the mixture
of vitamins C and E. However, 1000 lM of TreVO
strongly increased ERK phosphorylation, an eﬀect that
was partially blocked by wortmannin, PD98059 or a
mixture of vitamins E and C. In addition, the combi-
nation of these inhibitors showed an additive eﬀect
over the inhibition of ERK activation. Altogether
these results indicate that, although high doses of
TreVO stimulate ERK phosphorylation through the
PI3K-MEK-dependent pathway and also through an
oxidative mechanism, the inhibition of cell proliferation
does not seem to be associated with the activation of
these pathways.
In relation to cell diﬀerentiation, the new complex
behaves like an inhibitory agent, as has been demon-
strated by the inhibition of the speciﬁc ALP activity. It is
important to stress that TreVO inhibited cell diﬀerenti-
ation at low doses (5–25 lM). To investigate the mech-
anism by which the complex produced this eﬀect, we
included diﬀerent inhibitors such as wortmannin,
PD98059 and a mixture of vitamins E and C in the
diﬀerentiation assays. These agents were unable to re-
verse the inhibition produced by TreVO on cell diﬀer-
entiation. Thus, the osteoblastic diﬀerentiation does not
seem to be mediated by the PI3-K/ERK pathway or the
formation of ROS.
Among the cellular events evoked by insulin, the
glucose consumption is assumed to occur by the acti-
vation of PI3-K, as has been demonstrated in rat
adipocytes [77] and rat skeletal muscle [78]. These ob-
servations indicate that PI3-K is essential for insulin-
stimulated glucose consumption in several cell types.
However, other authors have suggested that vanadate
and pervanadate stimulate glucose consumption in
muscle cells by a mechanism independent of PI3-K [85].
Our present results are in agreement with the latter ob-
servations. Insulin and TreVO stimulated the glucose
consumption in osteoblast-like cells, but the PI3-K in-
hibitor wortmannin did not abrogate the eﬀect of these
agents.
In conclusion, the results of this work are relevant to
demonstrate the correlation between several biological
eﬀects and the signal transduction pathways involved in
the action of a new vanadium(IV) complex with treha-
lose. This compound could be a potential good candi-
date for therapeutic applications in the treatment of
diseases such as Diabetes mellitus.
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